ENHANCED DELIVERY OF ALPHA INTERFERON FOR GENTIAL HERPES

复发性生殖器疱疹感染仍然是一个重大的疾病问题。虽然口服阿昔洛韦已被证明是有效的，但它不是治愈的，它需要每天服用才能有效，而且价格昂贵。此外，口服阿昔洛韦不能减少反复感染的症状，长期使用的效果尚不清楚。当然，需要新的和改进的疗法。对局部应用干扰素的研究表明，干扰素具有一定的临床益处。然而，通过将干扰素更有效地输送到适当的靶细胞，干扰素的抗病毒和免疫学益处可以显著增强。在这项提案中，我们计划在体外黏膜转运模型中系统地研究干扰素的配方，使用一种能够增强蛋白质和多肽输送的试剂。使用这一模型将使我们能够快速评估潜在的配方，而不需要临床试验的难度、时间和费用。这项拟议的研究将导致确定一种外用凝胶配方，该配方可提供具有治疗生殖器疱疹强大潜力的干扰素。建议的商业应用：本建议中描述的研究将导致开发一种稳定有效的含有干扰素的凝胶，用于局部治疗复发性生殖器疱疹病毒感染。

Recurrent genital herpes infection remains a significant disease problem. While oral acylovir have been shown to be effective it is not curative, it requires daily administration to be efficacious and is expensive. In addition oral acyclovir does not reduce the symptoms of recurrent infections and the effects of long term use are unknown. Certainly new and improved therapies are needed. Investigations on the use of topically applied interferon have demonstrated some clinical benefit. However, the anti-viral and immunological benefits of interferon could be significantly enhanced by more effective delivery of interferon to appropriate target cells. In this proposal we plan to systematically investigate formulation of interferon with an agent that enhances delivery of proteins and peptides in an in vitro model of mucosal membrane transport. Use of this model will allow us to quickly evaluate potential formulations without the difficulty, time and expense of clinical trials. The proposed research should result in the identification of a topical gel formulation that delivers interferon with strong potential for treating genital herpes. PROPOSED COMMERCIAL APPLICATIONS: Research described in this proposal should lead to development of a stable and efficacious interferon containing gel for the topical treatment of recurrent genital herpes virus infections.